RadNet, Inc.
78.84-0.26 (-0.33%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · RDNT · USD
Key Stats
Market Cap
6.08BP/E (TTM)
-Basic EPS (TTM)
-0.20Dividend Yield
0%Recent Filings
8-K
Prospectus for stock resale filed
RadNet filed a prospectus supplement on October 21, 2025, registering up to 59,444 shares of common stock for resale by selling stockholders under its shelf registration. This routine filing, backed by counsel opinion from Reed Smith LLP, enables potential liquidity for those holders without direct company proceeds. No new capital raises involved. Selling stockholders gain resale flexibility.
8-K
RadNet boosts Q2 revenue, guidance
RadNet posted record Q2 revenue of $498.2 million, up 8.4% from last year, fueled by 9.0% growth in advanced imaging volumes and 30.9% surge in Digital Health revenue to $20.7 million. Adjusted EBITDA climbed 12.3% to $81.2 million, lifting margins to 16.3%. Volumes grew. The company raised 2025 guidance, targeting $1.850-$1.900 billion in revenue and $271-$279 million in Adjusted EBITDA, while cash swelled to $833.2 million.
10-Q
Q2 FY2025 results
RadNet's Q2 revenue climbed 8.4% year-over-year to $498.2M, fueled by 4.4% same-center growth and acquisitions, while operating income dipped 11.3% to $30.9M amid higher medical supplies and staffing costs. Gross margin held steady at 13.8%, but net income attributable to common stockholders swung to $14.5M profit from a $3.0M loss, thanks to lower interest expense of $17.2M (down 34.1% y/y) after refinancing. Acquisitions added $32.0M in goodwill, including See-Mode Technologies for $28.7M (cash/holdback/contingent mix), bolstering AI capabilities. Cash swelled to $833.2M with $161.8M operating cash flow; total debt stands at $1.1B under term loans maturing 2027-2031, with $324.6M revolver availability. Free cash flow hit $60.1M (derived). Yet reimbursement pressures from payors loom large.
8-K
DeepHealth acquires iCAD
RadNet's DeepHealth subsidiary closed its acquisition of iCAD on July 17, 2025, merging iCAD's AI breast health tech into its portfolio. This bolsters DeepHealth's AI solutions for cancer detection, expanding reach to over 1,500 global sites and 10 million annual mammograms. Integration promises workflow gains, yet hinges on retaining talent and navigating regulatory hurdles.
8-K
RadNet adds $100M term loan
RadNet secured a $100 million incremental term loan from Barclays on June 11, 2025, adding to its existing $868.4 million term loan under the amended credit agreement. Proceeds will fund future acquisitions and general corporate purposes, boosting quarterly principal payments to $2.4 million from $2.2 million while keeping the April 18, 2031 maturity intact. This bolsters RadNet's $717 million cash position as of March 31, 2025. It fuels strategic growth.
IPO
Website
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
DGX
Quest Diagnostics Incorporated
174.78-3.50
FONR
Fonar Corporation
15.33-0.06
GEHC
GE HealthCare Technologies Inc.
77.38-2.02
GH
Guardant Health, Inc.
72.27+2.69
NEO
NeoGenomics, Inc.
10.28+0.36
NNOX
NANO-X IMAGING LTD
3.74-0.15
ONMD
OneMedNet Corp
2.37+0.17
QTIH
QT Imaging Holdings, Inc.
6.95-0.12
RADX
Radiopharm Theranostics Limited
5.01-0.05